Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This approved ANDA is therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution, 0.004%, of Sandoz Inc. Travoprost ophthalmic solution is used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The estimated market size for Travoprost Ophthalmic Solution USP, 0.004%, was US$ 61 million for the twelve months ending September 2025, according to IQVIA. Alembic Pharmaceuticals has a total of 232 ANDA approvals from the USFDA, comprising 212 final approvals and 20 tentative approvals.